🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "huge turning point" in the effort against superbug strains of the pathogen, according to scientists.

An International Public Health Issue

Cases of gonorrhoea are increasing globally, with estimates suggesting more than 82 million infections per year. Especially elevated rates are observed in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. In England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary development in the face of growing infection rates, the spread of superbugs and the very limited treatment choices at this time.”

Medical experts are increasingly worried about the increase in treatment-resistant strains. The World Health Organization has classified it as a "critical concern". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Receive Approval

One new antibiotic, alternatively called a brand name, was cleared by the American regulatory agency in December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Scientists hope that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This drug, which is additionally indicated for UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This approval marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Testing Data and Worldwide Availability

As per findings detailed in a major medical journal, zoliflodacin successfully treated more than 90% of uncomplicated infections. This places it at an equal footing with the typical regimen, which involves an injection and a pill. The study involved nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the rights to license and sell the drug in many developing nations.

Doctors treating patients have voiced optimism. Access to a single-dose, oral treatment such as this is hailed as a "critical tool" for gonorrhoea control. This is considered essential to alleviate the strain of the illness for patients and to halt the transmission of untreatable gonorrhoea worldwide.